|
Gene: MED30 |
Gene summary for MED30 |
Gene summary. |
Gene information | Species | Human | Gene symbol | MED30 | Gene ID | 90390 |
Gene name | mediator complex subunit 30 | |
Gene Alias | MED30S | |
Cytomap | 8q24.11 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96HR3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
90390 | MED30 | P48T-E | Human | Esophagus | ESCC | 2.22e-24 | 5.20e-01 | 0.0959 |
90390 | MED30 | P49T-E | Human | Esophagus | ESCC | 1.07e-16 | 1.68e+00 | 0.1768 |
90390 | MED30 | P52T-E | Human | Esophagus | ESCC | 4.71e-27 | 8.26e-01 | 0.1555 |
90390 | MED30 | P54T-E | Human | Esophagus | ESCC | 6.72e-22 | 6.83e-01 | 0.0975 |
90390 | MED30 | P56T-E | Human | Esophagus | ESCC | 2.30e-10 | 1.36e+00 | 0.1613 |
90390 | MED30 | P57T-E | Human | Esophagus | ESCC | 9.52e-18 | 4.79e-01 | 0.0926 |
90390 | MED30 | P61T-E | Human | Esophagus | ESCC | 5.77e-13 | 2.36e-01 | 0.099 |
90390 | MED30 | P62T-E | Human | Esophagus | ESCC | 6.54e-76 | 1.30e+00 | 0.1302 |
90390 | MED30 | P65T-E | Human | Esophagus | ESCC | 5.73e-23 | 4.96e-01 | 0.0978 |
90390 | MED30 | P74T-E | Human | Esophagus | ESCC | 1.35e-40 | 1.28e+00 | 0.1479 |
90390 | MED30 | P75T-E | Human | Esophagus | ESCC | 2.71e-52 | 1.07e+00 | 0.1125 |
90390 | MED30 | P76T-E | Human | Esophagus | ESCC | 1.24e-34 | 7.28e-01 | 0.1207 |
90390 | MED30 | P79T-E | Human | Esophagus | ESCC | 6.12e-42 | 8.39e-01 | 0.1154 |
90390 | MED30 | P80T-E | Human | Esophagus | ESCC | 7.71e-56 | 1.64e+00 | 0.155 |
90390 | MED30 | P82T-E | Human | Esophagus | ESCC | 2.87e-10 | 7.81e-01 | 0.1072 |
90390 | MED30 | P83T-E | Human | Esophagus | ESCC | 2.17e-50 | 1.68e+00 | 0.1738 |
90390 | MED30 | P84T-E | Human | Esophagus | ESCC | 5.69e-16 | 1.04e+00 | 0.0933 |
90390 | MED30 | P89T-E | Human | Esophagus | ESCC | 2.19e-20 | 1.53e+00 | 0.1752 |
90390 | MED30 | P91T-E | Human | Esophagus | ESCC | 5.85e-12 | 1.75e+00 | 0.1828 |
90390 | MED30 | P107T-E | Human | Esophagus | ESCC | 6.89e-34 | 9.04e-01 | 0.171 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009872714 | Esophagus | ESCC | maintenance of cell number | 90/8552 | 134/18723 | 3.94e-07 | 5.43e-06 | 90 |
GO:001982714 | Esophagus | ESCC | stem cell population maintenance | 88/8552 | 131/18723 | 5.23e-07 | 6.97e-06 | 88 |
GO:00063673 | Esophagus | ESCC | transcription initiation from RNA polymerase II promoter | 56/8552 | 77/18723 | 1.30e-06 | 1.59e-05 | 56 |
GO:000635211 | Esophagus | ESCC | DNA-templated transcription, initiation | 86/8552 | 130/18723 | 1.88e-06 | 2.19e-05 | 86 |
GO:00602603 | Esophagus | ESCC | regulation of transcription initiation from RNA polymerase II promoter | 25/8552 | 33/18723 | 4.30e-04 | 2.43e-03 | 25 |
GO:200014212 | Esophagus | ESCC | regulation of DNA-templated transcription, initiation | 29/8552 | 40/18723 | 5.32e-04 | 2.93e-03 | 29 |
GO:20001443 | Esophagus | ESCC | positive regulation of DNA-templated transcription, initiation | 21/8552 | 31/18723 | 1.10e-02 | 3.70e-02 | 21 |
GO:001982711 | Liver | Cirrhotic | stem cell population maintenance | 48/4634 | 131/18723 | 1.58e-03 | 1.03e-02 | 48 |
GO:0006367 | Liver | Cirrhotic | transcription initiation from RNA polymerase II promoter | 31/4634 | 77/18723 | 1.91e-03 | 1.20e-02 | 31 |
GO:009872711 | Liver | Cirrhotic | maintenance of cell number | 48/4634 | 134/18723 | 2.70e-03 | 1.58e-02 | 48 |
GO:0060260 | Liver | Cirrhotic | regulation of transcription initiation from RNA polymerase II promoter | 15/4634 | 33/18723 | 7.61e-03 | 3.60e-02 | 15 |
GO:2000142 | Liver | Cirrhotic | regulation of DNA-templated transcription, initiation | 17/4634 | 40/18723 | 1.04e-02 | 4.61e-02 | 17 |
GO:00063671 | Liver | HCC | transcription initiation from RNA polymerase II promoter | 52/7958 | 77/18723 | 7.87e-06 | 9.27e-05 | 52 |
GO:0006352 | Liver | HCC | DNA-templated transcription, initiation | 78/7958 | 130/18723 | 4.19e-05 | 4.11e-04 | 78 |
GO:00987272 | Liver | HCC | maintenance of cell number | 77/7958 | 134/18723 | 3.32e-04 | 2.33e-03 | 77 |
GO:20001421 | Liver | HCC | regulation of DNA-templated transcription, initiation | 28/7958 | 40/18723 | 4.01e-04 | 2.71e-03 | 28 |
GO:00602601 | Liver | HCC | regulation of transcription initiation from RNA polymerase II promoter | 24/7958 | 33/18723 | 4.24e-04 | 2.85e-03 | 24 |
GO:00198272 | Liver | HCC | stem cell population maintenance | 75/7958 | 131/18723 | 4.58e-04 | 3.04e-03 | 75 |
GO:2000144 | Liver | HCC | positive regulation of DNA-templated transcription, initiation | 21/7958 | 31/18723 | 4.01e-03 | 1.76e-02 | 21 |
GO:0060261 | Liver | HCC | positive regulation of transcription initiation from RNA polymerase II promoter | 17/7958 | 25/18723 | 8.94e-03 | 3.45e-02 | 17 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0491928 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa04919113 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa0491912 | Liver | HCC | Thyroid hormone signaling pathway | 75/4020 | 121/8465 | 8.76e-04 | 3.38e-03 | 1.88e-03 | 75 |
hsa0491913 | Liver | HCC | Thyroid hormone signaling pathway | 75/4020 | 121/8465 | 8.76e-04 | 3.38e-03 | 1.88e-03 | 75 |
hsa0491926 | Oral cavity | OSCC | Thyroid hormone signaling pathway | 73/3704 | 121/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 73 |
hsa04919112 | Oral cavity | OSCC | Thyroid hormone signaling pathway | 73/3704 | 121/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 73 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
MED30 | TUF | Colorectum | CRC | ARID3A,SOX4,BICC1, etc. | 4.77e-02 |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MED30 | SNV | Missense_Mutation | novel | c.132N>G | p.Ile44Met | p.I44M | Q96HR3 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MED30 | SNV | Missense_Mutation | novel | c.270N>T | p.Arg90Ser | p.R90S | Q96HR3 | protein_coding | deleterious(0) | possibly_damaging(0.503) | TCGA-VS-A9UU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MED30 | SNV | Missense_Mutation | rs764507160 | c.247C>T | p.Arg83Cys | p.R83C | Q96HR3 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
MED30 | SNV | Missense_Mutation | c.104N>A | p.Arg35His | p.R35H | Q96HR3 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MED30 | SNV | Missense_Mutation | c.302A>T | p.Glu101Val | p.E101V | Q96HR3 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
MED30 | SNV | Missense_Mutation | novel | c.367T>A | p.Ser123Thr | p.S123T | Q96HR3 | protein_coding | tolerated(0.72) | benign(0.078) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MED30 | SNV | Missense_Mutation | novel | c.453N>C | p.Gln151His | p.Q151H | Q96HR3 | protein_coding | tolerated(0.55) | possibly_damaging(0.477) | TCGA-AJ-A3TW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MED30 | SNV | Missense_Mutation | c.252N>T | p.Gln84His | p.Q84H | Q96HR3 | protein_coding | tolerated(0.06) | benign(0.025) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MED30 | SNV | Missense_Mutation | c.523N>A | p.Ala175Thr | p.A175T | Q96HR3 | protein_coding | tolerated(1) | possibly_damaging(0.851) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MED30 | SNV | Missense_Mutation | novel | c.212N>T | p.Tyr71Phe | p.Y71F | Q96HR3 | protein_coding | tolerated(0.54) | benign(0.239) | TCGA-DD-AAVV-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |